NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Parkinson’s Disease (PD) is the fastest-growing neurological disorder and only symptomatic treatment is available. Zebrafish are ideally suited for high-throughput screening of disease modifying drugs and mechanistic studies. Mutations in PARK7 are associated with early onset familial PD, however also idiopathic PD patients without known mutations in PARK7 show altered subcellular location and levels of its protein product DJ-1 in pathological tissues. Here, we show that PARK7-/- zebrafish already at their larval stage show a correlation between reduced number of dopaminergic neurons and motor dysfunction. Additionally, PD associated prodromal symptoms as reduced sensory function, increased sleep latency and light phase sleepiness were also observed. The 1-methyl-4-phenylpyridinium (MPP+) exposed PD model did not reproduce similar sleep disturbances. This is the first stable genetic larval zebrafish model of Parkinson’s disease which shows both motor and non-motor symptoms together with a reduction in dopaminergic neurons. The model should therefore be highly valuable as a tool for PD related drug screening and mechanistic studies.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.